Blood Res.  2022 Jun;57(2):158-161. 10.5045/br.2022.2020305.

Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease

• Liam CCK
• Boo YL
• Chong SL
• Sathar J
• Ong TC
• Tan SM

• KMID: 2530883
• DOI: http://doi.org/10.5045/br.2022.2020305

Figure

• 

  Fig. 1 Immunophenotyping exhibits a common B phenotype (CD34- positive, CD19-positive, and CD10- positive) with aberrant expression of CD13 and CD33 (data not shown here).

Reference

1. Moorman AV, Harrison CJ, Buck GA, et al. 2007; Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 109:3189–97. DOI: 10.1182/blood-2006-10-051912. PMID: 17170120.

2. Fielding AK, Rowe JM, Buck G, et al. 2014; UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 123:843–50. DOI: 10.1182/blood-2013-09-529008. PMID: 24277073. PMCID: PMC3916877.

3. Rousselot P, Coudé MM, Gokbuget N, et al. 2016; Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 128:774–82. DOI: 10.1182/blood-2016-02-700153. PMID: 27121472. PMCID: PMC5085255.

4. Jabbour E, Short NJ, Ravandi F, et al. 2018; Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 5:e618–27. DOI: 10.1016/S2352-3026(18)30176-5. PMID: 30501869.

5. Dombret H, Gabert J, Boiron JM, et al. 2002; Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood. 100:2357–66. DOI: 10.1182/blood-2002-03-0704. PMID: 12239143.

6. Chalandon Y, Thomas X, Hayette S, et al. 2015; Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 125:3711–9. DOI: 10.1182/blood-2015-02-627935. PMID: 25878120.

7. Foà R, Bassan R, Vitale A, et al. 2020; Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 383:1613–23. DOI: 10.1056/NEJMoa2016272. PMID: 33085860.

8. Park JH, Rivière I, Gonen M, et al. 2018; Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 378:449–59. DOI: 10.1056/NEJMoa1709919. PMID: 29385376. PMCID: PMC6637939.

9. Martinelli G, Boissel N, Chevallier P, et al. 2017; Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 35:1795–802. DOI: 10.1200/JCO.2016.69.3531. PMID: 28355115.

10. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. 2016; Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 375:740–53. DOI: 10.1056/NEJMoa1509277. PMID: 27292104. PMCID: PMC5594743.

11. Weiss MA, Aliff TB, Tallman MS, et al. 2002; A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer. 95:581–7. DOI: 10.1002/cncr.10707. PMID: 12209751.

12. Giebel S, Czyz A, Ottmann O, et al. 2016; Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 122:2941–51. DOI: 10.1002/cncr.30130. PMID: 27309127.